926 results found
Ratner RE, Cannon CP, Gerstein HC, et al., 2008, Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics, AMERICAN HEART JOURNAL, Vol: 156, Pages: 1074-1079, ISSN: 0002-8703
Gonzalo N, Garcia-Garcia HM, Ligthart J, et al., 2008, Coronary plaque composition as assessed by greyscale intravascular ultrasound and radiofrequency spectral data analysis, INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, Vol: 24, Pages: 811-818, ISSN: 1569-5794
Ramcharitar S, Meliga E, Kirschbaum SW, et al., 2008, Acute hemodynamic changes in percutaneous transluminal septal coil embolization for hypertrophic obstructive cardiomyopathy, NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, Vol: 5, Pages: 806-810, ISSN: 1743-4297
Ramcharitar S, van Geuns RJ, Patterson M, et al., 2008, A Randomized Comparison of the Magnetic Navigation System Versus Conventional Percutaneous Coronary Intervention, CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol: 72, Pages: 761-770, ISSN: 1522-1946
Tanimoto S, Bruining N, van Domburg RT, et al., 2008, Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque Morphology, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 52, Pages: 1616-1620, ISSN: 0735-1097
Mercado N, Brugts JJ, Ix JH, et al., 2008, Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial), AMERICAN JOURNAL OF CARDIOLOGY, Vol: 102, Pages: 1151-1155, ISSN: 0002-9149
Segers D, Garcia-Garcia HM, Cheng C, et al., 2008, A primer on the immune system in the pathogenesis and treatment of atherosclerosis., EuroIntervention, Vol: 4, Pages: 378-390, ISSN: 1774-024X
Atherosclerosis is currently appreciated as a disease with a large inflammatory component. The underlying mechanisms, which are uncovered in a rapid pace, are greatly interconnected and as such very complex. Nevertheless, for clinicians it is important have some degree of insight in these immunologic mechanisms in order to interpret the current research advances. The aim of this review is to supply clinicians with this knowledge, avoiding too much detail. All the relevant immunologic basics will be discussed at first, followed by the immunity related theories of atherosclerosis. Finally, current and new immune-modulatory therapies will be discussed.
Vranckx P, Meliga E, De Jaegere PPT, et al., 2008, The TandemHeart, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience., EuroIntervention, Vol: 4, Pages: 331-337, ISSN: 1774-024X
AIMS: Percutaneous coronary interventions (PCI) in high-risk cardiac patients are preferentially referred to specialised myocardial intervention centres (MIC). Included in this group are patients with a haemodynamic collapse or high likelihood of haemodynamic collapse, either during balloon inflation or with acute vessel closure. The TandemHeart, a percutaneous transseptal left ventricular assist (PTVA) that can be introduced using standard catheterisation laboratory techniques, offers interesting perspectives to reduce procedural risks. METHODS AND RESULTS: Between September 2000 to July 2006, The TandemHeart, supported the circulation of 23 patients (age: range 46-74, mean 59) admitted to our centre for high risk, either emergency or elective, PCI. Successful implantation was achieved in 100% of patients. The mean time for implementation of circulatory support was 35 minutes (range 16-62). The index PCI was successful in all patients except two. A pump flow up to 4L/min was achieved with significant reduction of left ventricular filling pressures, pulmonary capillary wedge pressure and with significant increase of systemic arterial pressures. Duration of support ranged from 1-222 hours (mean 31+/-49.8 hours). Five patients died with the TandemHeart in place, four of whom were in irreversible cardiogenic shock at admission. Mild to moderate access site bleeding was seen in 27% of patients. One patient experienced a loge syndrome of the leg. Core temperature (Ct) decreased to <36.5 degrees C in six patients, profound hypothermia (Ct <35 degrees C) was observed in two patients. There was no technical device failure. CONCLUSIONS: The TandemHeart - PTVA provides effective, total left ventricular support in very high risk PCI settings. The rate of device related cardiac and vascular complications was acceptable.
van Twisk P-H, Daemen J, Kukreja N, et al., 2008, Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts., EuroIntervention, Vol: 4, Pages: 311-317, ISSN: 1774-024X
OBJECTIVES: Recently, concerns were raised about the relative long-term safety and efficacy of drug-eluting stents (DES) in saphenous vein bypass grafts (SVG). Our objective was to assess the 4-year relative safety and efficacy of the unrestricted use of drug-eluting stents (DES) as compared to bare metal stents (BMS) in saphenous vein bypass grafts (SVG). METHODS: Between April 16, 2002 and December 2005 a total of 122 consecutive patients were treated with either sirolimus- or paclitaxel-eluting stents for saphenous vein graft disease. These patients were compared with 128 consecutive patients treated with BMS in the immediate preceding period (January 1, 2000 to April 2002). RESULTS: At 4-years the cumulative survival rate in the DES group was 77.5% versus 73.0% in the BMS group (adjusted HR 1.09; 95% CI 0.63-1.90, Logrank p=0.65). The cumulative survival free of major adverse cardiac events (MACE: death, myocardial infarction and target vessel revascularisation) was 61.5% vs. 46.8% in the DES and BMS groups respectively (adjusted HR 0.77, 95% CI; 0.51-1.16) due to a higher event free survival of clinically driven target vessel revascularisation in the DES group as compared to the BMS group (81.6% vs. 69.0%; adjusted HR 0.53; 95% CI 0.27-1.05). CONCLUSIONS: In the present study, the use of DES for SVG PCI was associated a similar safety profile and there was a trend towards lower rates of TVR and MACE at four years as compared to BMS.
De Jaegere PPT, Piazza N, Galema TW, et al., 2008, Early echocardiographic evaluation following percutaneous implantation with the self-expanding CoreValve Revalving System aortic valve bioprosthesis., EuroIntervention, Vol: 4, Pages: 351-357, ISSN: 1774-024X
AIMS: Although safety and feasibility studies have been published, there are few reports dedicated to the echocardiographic evaluation of patients following percutaneous aortic valve replacement (PAVR). This report describes the early echocardiographic evaluation of patients undergoing PAVR with the CoreValve Revalving System. METHODS AND RESULTS: The population consisted of 33 consecutive patients with aortic stenosis who underwent successful PAVR. Echocardiograms were performed pre-treatment (123+/-110 days prior), post-treatment (6+/-2 days) and post-discharge (80+/-64 days). Aortic valve function and left ventricular dimensions, systolic and diastolic function were assessed pre- and post-implantation. The mean age was 81+/-7 years and the mean Logistic Euroscore was 20+/-12. Following PAVR, the mean transaortic valve gradient decreased (46+/-16 mmHg pre-treatment vs. 12+/-7 mmHg post-treatment vs. 9+/-5 mmHg post-discharge, p<0.001) and the mean effective orifice area increased (0.75+/-0.23 cm2 pre-treatment vs. 1.97+/-0.85 cm2 post-treatment vs. 1.72+/-0.45 cm2 post-discharge, p<0.001). There was no significant change in mean ejection fraction (41+/-12% pre-treatment vs. 46+/-15% post-treatment vs. 44+/-13% post-discharge, p=0.44). Approximately two-thirds of patients had no change in diastolic function at follow-up. CONCLUSION: Following implantation, there was a sustained decrease in aortic valve gradient and increase in aortic valve area. In addition, the mean ejection fraction did not change significantly and in the majority of patients, diastolic function was unchanged.
Serruys PW, 2008, Together, we can truly insure the future., EuroIntervention, Vol: 4, ISSN: 1774-024X
Tsuchida K, Daemen J, Tanimoto S, et al., 2008, Two-year outcome of the use of paclitaxel-eluting stents in aorto-ostial lesions, INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol: 129, Pages: 348-353, ISSN: 0167-5273
Serruys PW, Windecker S, Buszman P, et al., 2008, Leaders - A Randomized Comparison Of A Biolimus-A9 Eluting Stent With A Sirolimus-eluting Stent For Percutaneous Coronary Intervention. 12 Months Results, 20th Annual Transcatheter Cardiovascular Therapeutics Conference, Publisher: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, Pages: 160I-161I, ISSN: 0002-9149
Barlis P, Regar E, Dimopoulos K, et al., 2008, A Randomized Optical Coherence Tomography Study of an Erodible versus Durable Polymer-Coated Limus-Eluting Stent, 20th Annual Transcatheter Cardiovascular Therapeutics Conference, Publisher: EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, Pages: 15I-15I, ISSN: 0002-9149
Steendijk P, Meliga E, Valgimigli M, et al., 2008, Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy, HEART, Vol: 94, Pages: 1318-1322, ISSN: 1355-6037
Gijsen FJH, Wentzel JJ, Thury A, et al., 2008, Strain distribution over plaques in human coronary arteries relates to shear stress, AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, Vol: 295, Pages: H1608-H1614, ISSN: 0363-6135
Kukreja N, Onuma Y, Garcia-Garcia H, et al., 2008, Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Long-Term Outcome After Bare Metal and Drug-Eluting Stent Implantation, CIRCULATION-CARDIOVASCULAR INTERVENTIONS, Vol: 1, Pages: 103-110, ISSN: 1941-7640
Garcia-Garcia HM, Gonzalo N, Tanimoto S, et al., 2008, Characterization of edge effects with paclitaxel-eluting stents using serial intravascular ultrasound radiofrequency data analysis: The BETAX (BEside TAXus) study, REVISTA ESPANOLA DE CARDIOLOGIA, Vol: 61, Pages: 1013-1019, ISSN: 0300-8932
Wiemer M, Seth A, Chandra P, et al., 2008, Systemic exposure of everolimus after stent implantation: a pharmacokinetic study., Am Heart J, Vol: 156, Pages: 751.e1-751.e7
OBJECTIVES: We evaluated the pharmacokinetics of the eluted everolimus by assessing systemic drug release and distribution of everolimus-eluting stents. BACKGROUND: Drugs eluted by a coronary stent might cause adverse events such as tumors, infections, or noncardiac death. The systemic exposure of the drugs is unknown because there are only limited data about pharmacokinetics of drug-eluting stents in humans. METHODS: Venous blood samples in a subset of 39 patients were drawn just before implantation of the first stent (baseline, 0-minute time point) and at 10 and 30 minutes and 1, 2, 4, 6, 12, 24, 36, 48, 72, 168, and 720 hours (30 days) after completion of implantation of the last stent. Whole blood concentrations of everolimus were determined using a sensitive validated high-performance liquid chromatography mass spectrometry/mass spectrometry method. RESULTS: The total dose of everolimus received by the patients ranged from 53 to 588 microg. The last time point up to which whole blood concentrations could be quantified ranged per patient from 4 to 720 hours after implantation of the last stent. Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL. CONCLUSION: This study confirms the limited exposure to the systemic circulation of the eluted drug with the use of the XIENCE V Everolimus-Eluting Coronary Stent System (Abbott Vascular, Santa Clara, CA). Therefore, a systemic cause of adverse events is unlikely.
Gonzalo N, Serruys PW, Regar E, 2008, Optical coherence tomography: clinical applications and the evaluation of DES., Minerva Cardioangiol, Vol: 56, Pages: 511-525, ISSN: 0026-4725
Optical coherencet tomography (OCT) is a light-based imaging modality that can provide in vivo high-resolution images of the coronary artery. In the last years there has been a continuous technical development that has improved the image quality and has simplified the acquisition procedure in order to spread the clinical applicability of this technique. Due to its high resolution OCT, can be a very valuable tool for the evaluation of the coronary vessel wall, the acute and long-term impact of catheter-based intervention on plaque structure and vessel architecture and the assessment of stents. During stenting, OCT offers the possibility to evaluate stent apposition in great detail and can identify the presence of vessel injury due to stent implantation. At follow-up, the tissue coverage of individual struts can be imaged with OCT. This is of increasing interest in drug-eluting stents in which the neointimal proliferation is inhibited to such extent that it might not be visualized with conventional intracoronary imaging techniques such as IVUS. Regarding the analysis of the coronary vessel wall, OCT holds promise for the identification of thin cap fibroatheroma due to its ability to provide information about plaque composition, presence of macrophages and thickness of the fibrous cap.
Wenaweser P, Daemen J, Zwahlen M, et al., 2008, Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice - 4-year results from a large 2-institutional cohort study, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 52, Pages: 1134-1140, ISSN: 0735-1097
Serruys PW, Garcia-Garcia HM, Buszman P, et al., 2008, Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque, CIRCULATION, Vol: 118, Pages: 1172-1182, ISSN: 0009-7322
Daemen J, Boersma E, Flather M, et al., 2008, Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease - A meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials, CIRCULATION, Vol: 118, Pages: 1146-1154, ISSN: 0009-7322
Rivero-Ayerza M, Jessurun E, Ramcharitar S, et al., 2008, Magnetically guided left ventricular lead implantation based on a virtual three-dimensional reconstructed image of the coronary sinus, EUROPACE, Vol: 10, Pages: 1042-1047, ISSN: 1099-5129
Barlis P, Ramcharitar S, Redwood S, et al., 2008, Long-term outcomes of bifurcation stenting using the culotte technique with drug-eluting stents, EUROPEAN HEART JOURNAL, Vol: 29, Pages: 631-632, ISSN: 0195-668X
Chieffo A, Park S-J, Meliga E, et al., 2008, Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry, EUROPEAN HEART JOURNAL, Vol: 29, Pages: 2108-2115, ISSN: 0195-668X
Windecker S, Serruys PW, Wandel S, et al., 2008, Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial, LANCET, Vol: 372, Pages: 1163-1173, ISSN: 0140-6736
Meijboom WB, Van Mieghem CAG, van Pelt N, et al., 2008, Comprehensive assessment of coronary artery stenoses - Computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 52, Pages: 636-643, ISSN: 0735-1097
Barlis P, Serruys PW, Gonzalo N, et al., 2008, Assessment of culprit and remote coronary narrowings using optical coherence tomography with long-term outcomes, AMERICAN JOURNAL OF CARDIOLOGY, Vol: 102, Pages: 391-395, ISSN: 0002-9149
Meliga E, Valgimigli M, Buszman P, et al., 2008, Percutaneous coronary intervention or coronary artery bypass graft for unprotected left main coronary artery disease: The endless debate, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 52, Pages: 582-584, ISSN: 0735-1097
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.